Guselkumab (Tremfya®)

Assessment Status Assessment process complete
Drug Guselkumab
Brand Tremfya®
Indication For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 01/12/2017
Rapid review completed 06/02/2018
Rapid review outcome Full Pharmacoeconomic Evaluation not recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations: April 2018